Straits Times Index
3,313.35 +9.69 (+0.29%) S&P 500
5,224.27 +2.85 (+0.05%) Dow
39,458.83 +27.32 (+0.07%) Nasdaq
16,422.14 +33.90 (+0.21%) Bitcoin USD
61,605.25 -1,213.16 (-1.93%) CMC Crypto 200
1,275.70 -15.70 (-1.22%)
Equillium, Inc. (EQ)
| Previous close | 1.5400 |
| Open | 1.5400 |
| Bid | 1.4700 x 100 |
| Ask | 1.6000 x 100 |
| Day's range | 1.4700 - 1.6100 |
| 52-week range | 0.4500 - 3.2500 |
| Volume | |
| Avg. volume | 242,077 |
| Market cap | 53.764M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
LA JOLLA, Calif., May 14, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono’s three-mo
- Business Wire
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
LA JOLLA, Calif., May 09, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development.
- Business Wire
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif., May 07, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Center in Chicago, Illinois, May 3 – 7.
